PortalPublikationenLongitudinal fluorescence hybridization reveals cytogenetic...

Longitudinal fluorescence hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation

Standard

Longitudinal fluorescence hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. / Merz, Maximilian; Jauch, Anna; Hielscher, Thomas; Mai, Elias K; Seckinger, Anja; Hose, Dirk; Bertsch, Uta; Neben, Kai; Raab, Marc S; Salwender, Hans; Blau, Igor W; Lindemann, Hans-Walter; Schmidt-Wolf, Ingo; Scheid, Christof; Haenel, Mathias; Weisel, Katja; Goldschmidt, Hartmut; Hillengass, Jens.

in: HAEMATOLOGICA, Jahrgang 102, Nr. 8, 08.2017, S. 1432-1438.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Merz, M, Jauch, A, Hielscher, T, Mai, EK, Seckinger, A, Hose, D, Bertsch, U, Neben, K, Raab, MS, Salwender, H, Blau, IW, Lindemann, H-W, Schmidt-Wolf, I, Scheid, C, Haenel, M, Weisel, K, Goldschmidt, H & Hillengass, J 2017, 'Longitudinal fluorescence hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation', HAEMATOLOGICA, Jg. 102, Nr. 8, S. 1432-1438. https://doi.org/10.3324/haematol.2017.168005

APA

Merz, M., Jauch, A., Hielscher, T., Mai, E. K., Seckinger, A., Hose, D., Bertsch, U., Neben, K., Raab, M. S., Salwender, H., Blau, I. W., Lindemann, H-W., Schmidt-Wolf, I., Scheid, C., Haenel, M., Weisel, K., Goldschmidt, H., & Hillengass, J. (2017). Longitudinal fluorescence hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. HAEMATOLOGICA, 102(8), 1432-1438. https://doi.org/10.3324/haematol.2017.168005

Vancouver

Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D et al. Longitudinal fluorescence hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. HAEMATOLOGICA. 2017 Aug;102(8):1432-1438. https://doi.org/10.3324/haematol.2017.168005

Bibtex

@article{125aeb38213c49f6a3cba2b5f38e4aac,
title = "Longitudinal fluorescence hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation",
abstract = "To investigate cytogenetic evolution after upfront autologous stem cell transplantation for newly diagnosed myeloma we retrospectively analyzed fluorescence in situ hybridization results of 128 patients with paired bone marrow samples from the time of primary diagnosis and at relapse. High-risk cytogenetic abnormalities (deletion 17p and/or gain 1q21) occurred more frequently after relapse (odds ratio: 6.33; 95% confidence interval: 1.86-33.42; P<0.001). No significant changes were observed for defined IGH translocations [t(4;14); t(11;14); t(14;16)] or hyperdiploid karyotypes between primary diagnosis and relapse. IGH translocations with unknown partners occurred more frequently at relapse. New deletion 17p and/or gain 1q21 were associated with cytogenetic heterogeneity, since some de novo lesions with different copy numbers were present only in subclones. No distinct baseline characteristics were associated with the occurrence of new high-risk cytogenetic abnormalities after progression. Patients who relapsed after novel agent-based induction therapy had an increased risk of developing high-risk aberrations (odds ratio 10.82; 95% confidence interval: 1.65-127.66; P=0.03) compared to those who were treated with conventional chemotherapy. Survival analysis revealed dismal outcomes regardless of whether high-risk aberrations were present at baseline (hazard ratio, 3.53; 95% confidence interval: 1.53-8.14; P=0.003) or developed at relapse only (hazard ratio, 3.06; 95% confidence interval: 1.09-8.59; P=0.03). Our results demonstrate cytogenetic evolution towards high-risk disease after autologous transplantation and underline the importance of repeated genetic testing in relapsed myeloma (EudraCT number of the HD4 trial: 2004-000944-26).",
keywords = "Chromosome Aberrations, Cytogenetic Analysis, Female, Humans, In Situ Hybridization, Fluorescence, Longitudinal Studies, Male, Middle Aged, Multiple Myeloma, Recurrence, Retrospective Studies, Transplantation, Autologous, Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't",
author = "Maximilian Merz and Anna Jauch and Thomas Hielscher and Mai, {Elias K} and Anja Seckinger and Dirk Hose and Uta Bertsch and Kai Neben and Raab, {Marc S} and Hans Salwender and Blau, {Igor W} and Hans-Walter Lindemann and Ingo Schmidt-Wolf and Christof Scheid and Mathias Haenel and Katja Weisel and Hartmut Goldschmidt and Jens Hillengass",
note = "Copyright{\textcopyright} 2017 Ferrata Storti Foundation.",
year = "2017",
month = aug,
doi = "10.3324/haematol.2017.168005",
language = "English",
volume = "102",
pages = "1432--1438",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "8",

}

RIS

TY - JOUR

T1 - Longitudinal fluorescence hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation

AU - Merz, Maximilian

AU - Jauch, Anna

AU - Hielscher, Thomas

AU - Mai, Elias K

AU - Seckinger, Anja

AU - Hose, Dirk

AU - Bertsch, Uta

AU - Neben, Kai

AU - Raab, Marc S

AU - Salwender, Hans

AU - Blau, Igor W

AU - Lindemann, Hans-Walter

AU - Schmidt-Wolf, Ingo

AU - Scheid, Christof

AU - Haenel, Mathias

AU - Weisel, Katja

AU - Goldschmidt, Hartmut

AU - Hillengass, Jens

N1 - Copyright© 2017 Ferrata Storti Foundation.

PY - 2017/8

Y1 - 2017/8

N2 - To investigate cytogenetic evolution after upfront autologous stem cell transplantation for newly diagnosed myeloma we retrospectively analyzed fluorescence in situ hybridization results of 128 patients with paired bone marrow samples from the time of primary diagnosis and at relapse. High-risk cytogenetic abnormalities (deletion 17p and/or gain 1q21) occurred more frequently after relapse (odds ratio: 6.33; 95% confidence interval: 1.86-33.42; P<0.001). No significant changes were observed for defined IGH translocations [t(4;14); t(11;14); t(14;16)] or hyperdiploid karyotypes between primary diagnosis and relapse. IGH translocations with unknown partners occurred more frequently at relapse. New deletion 17p and/or gain 1q21 were associated with cytogenetic heterogeneity, since some de novo lesions with different copy numbers were present only in subclones. No distinct baseline characteristics were associated with the occurrence of new high-risk cytogenetic abnormalities after progression. Patients who relapsed after novel agent-based induction therapy had an increased risk of developing high-risk aberrations (odds ratio 10.82; 95% confidence interval: 1.65-127.66; P=0.03) compared to those who were treated with conventional chemotherapy. Survival analysis revealed dismal outcomes regardless of whether high-risk aberrations were present at baseline (hazard ratio, 3.53; 95% confidence interval: 1.53-8.14; P=0.003) or developed at relapse only (hazard ratio, 3.06; 95% confidence interval: 1.09-8.59; P=0.03). Our results demonstrate cytogenetic evolution towards high-risk disease after autologous transplantation and underline the importance of repeated genetic testing in relapsed myeloma (EudraCT number of the HD4 trial: 2004-000944-26).

AB - To investigate cytogenetic evolution after upfront autologous stem cell transplantation for newly diagnosed myeloma we retrospectively analyzed fluorescence in situ hybridization results of 128 patients with paired bone marrow samples from the time of primary diagnosis and at relapse. High-risk cytogenetic abnormalities (deletion 17p and/or gain 1q21) occurred more frequently after relapse (odds ratio: 6.33; 95% confidence interval: 1.86-33.42; P<0.001). No significant changes were observed for defined IGH translocations [t(4;14); t(11;14); t(14;16)] or hyperdiploid karyotypes between primary diagnosis and relapse. IGH translocations with unknown partners occurred more frequently at relapse. New deletion 17p and/or gain 1q21 were associated with cytogenetic heterogeneity, since some de novo lesions with different copy numbers were present only in subclones. No distinct baseline characteristics were associated with the occurrence of new high-risk cytogenetic abnormalities after progression. Patients who relapsed after novel agent-based induction therapy had an increased risk of developing high-risk aberrations (odds ratio 10.82; 95% confidence interval: 1.65-127.66; P=0.03) compared to those who were treated with conventional chemotherapy. Survival analysis revealed dismal outcomes regardless of whether high-risk aberrations were present at baseline (hazard ratio, 3.53; 95% confidence interval: 1.53-8.14; P=0.003) or developed at relapse only (hazard ratio, 3.06; 95% confidence interval: 1.09-8.59; P=0.03). Our results demonstrate cytogenetic evolution towards high-risk disease after autologous transplantation and underline the importance of repeated genetic testing in relapsed myeloma (EudraCT number of the HD4 trial: 2004-000944-26).

KW - Chromosome Aberrations

KW - Cytogenetic Analysis

KW - Female

KW - Humans

KW - In Situ Hybridization, Fluorescence

KW - Longitudinal Studies

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Recurrence

KW - Retrospective Studies

KW - Transplantation, Autologous

KW - Clinical Trial

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.3324/haematol.2017.168005

DO - 10.3324/haematol.2017.168005

M3 - SCORING: Journal article

C2 - 28495913

VL - 102

SP - 1432

EP - 1438

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 8

ER -